Table 4 Univariate and multi-variate analysis of risk factor associated with 28-day mortality among patients with KP BSI
Variable | Survived (n = 126) | Died (n = 12) | Univariate analysis | Multi-variate analysis | ||
|---|---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | |||
Age (months), median (IQR) | 24.23 (0.91–107.55) | 32.41 (3.54–52.99) | – | 0.919 | – | – |
Male | 72 (57.1) | 8 (66.7) | – | 0.739 | – | – |
Underlying disease | 106 (84.1) | 12 (100) | – | 0.214 | – | – |
Hematologic malignancies | 60 (47.6) | 6 (50.0) | – | 0.875 | – | – |
Congenital anomalies | 16 (12.7) | 3 (25.0) | – | 0.457 | – | – |
Prematurity | 12 (9.5) | 1 (8.3) | – | 1.000 | – | – |
Malnutrition | 6 (4.8) | 1 (8.3) | – | 1.000 | – | – |
Immunodeficiencies | 6 (4.8) | 0 (0) | – | 1.000 | – | – |
Deep venous catheterization | 97 (77.0) | 11 (91.7) | – | 0.417 | – | – |
Mechanical ventilation | 10 (7.9) | 7 (58.3) | 16.240 (4.352–60.607) | < 0.001 | 9.502 (2.098–43.033) | 0.003 |
Organ dysfunction | 44 (34.9) | 9 (75.0) | 5.591 (1.439–21.718) | 0.016 | – | – |
Septic shock | 9 (7.1) | 6 (50.0) | 13.000 (3.476–48.623) | < 0.001 | 6.418 (1.342–30.686) | 0.020 |
Empirical treatment active in vitro | 76 (60.3) | 5 (41.7) | – | 0.233 | – | – |
Definitive treatment active in vitro a | 100 (79.4) | 5 (62.5) | – | 0.370 | – | – |
Carbapenem-including treatment a | 90 (71.4) | 5 (62.5) | – | 0.691 | – | – |
Isolation of CRKP | 44 (34.9) | 10 (83.3) | 9.318 (1.955–44.421) | 0.003 | 9.171 (1.546–54.416) | 0.015 |